Photosensitivity with Cipro

Medscape has recently reported that “The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise of the risks for photosensitivity and phototoxicity in patients receiving treatment with quinolone antibiotics such as ciprofloxacin, updated information regarding the risk for cardiomyopathy in patients receiving trastuzumab therapy, and the potential for developing Clostridium difficile–associated diarrhea more than 2 months after completion of antimicrobial therapy”.

CME credits are available for this subject through the Medscape website.

Other stories